Overexpression of TTRAP inhibits cell growth and induces apoptosis in osteosarcoma cells

Caihong Zhou, Qi Shen, Jinglun Xue, Chaoneng Ji* & Jinzhong Chen*
State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200433, China

TTRAP is a multi-functional protein that is involved in multiple aspects of cellular functions including cell proliferation, apoptosis and the repair of DNA damage. Here, we demonstrated that the lentivirus-mediated overexpression of TTRAP significantly inhibited cell growth and induced apoptosis in osteosarcoma cells. The ectopic TTRAP suppressed the growth and colony formation capacity of two osteosarcoma cell lines, U2OS and Saos-2. Cell apoptosis was induced in U2OS cells and the cell cycle was arrested at G2/M phase in Saos-2 cells. Exogenous expression of TTRAP in serum-starved U2OS and Saos-2 cells induced an increase in caspase-3/-7 activity and a decrease in cyclin B1 expression. In comparison with wild-type TTRAP, mutations in the 5'-tyrosyl-DNA phosphodiesterase activity of TTRAP, in particular TTRAP(E152A), showed decreased inhibitory activity on cell growth. These results may aid in clarifying the physiological functions of TTRAP, especially its roles in the regulation of cell growth and tumorigenesis. [BMB Reports 2013; 46(2): 113-118]

INTRODUCTION

Cancer is a malignant neoplasm that is associated with unregulated cell growth (1). The growth of healthy cells is strictly and intricately controlled by multiple genes involved in various functions, including cell proliferation, differentiation and apoptosis. Recently, a cellular protein, TRAF- and TNF receptor-associated protein (TTRAP), has stimulated interest because of its pleiotropic functions in the regulation of cell growth and tumorigenesis (2).

As a ubiquitously expressed protein, TTRAP has multiple effects on cell growth and tumorigenesis. It is involved in multiple signaling pathways associated with the inhibition of cell growth and the induction of apoptosis. Originally, TTRAP was reported to interact with members of the TNF receptor family and TNF receptor-associated factors (TRAFs) (3). In FOXO3a-induced apoptosis, it is upregulated together with signal proteins downstream of the TNF receptor (4). TTRAP was also denoted as ETS1-associated protein II (EAPII) for its inhibitory effects on ETS1 transcriptional activity and ETS1-dependent cell migration (5). In mammary cells, TTRAP has been associated with the TGF-β receptor-TRAF6-TAK1 signaling module and is involved in TGF-β-mediated apoptosis (6). TTRAP also promotes apoptosis in cytotoxic agent (hydroquinone)-treated HL-60 cells (7). In zebrafish, TTRAP might work as a component of the Nodal/activin signaling pathway and an important regulator of embryogenesis (8). However, several lines of evidence have indicated that TTRAP promotes cell growth and oncogenesis. TTRAP protects neuroblastoma cells from apoptosis induced by proteasome impairment (9). Recently, Li et al. reported that TTRAP facilitated the oncogenesis of non-small-cell lung carcinoma (NSCLC) cells through the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK-ERK) signaling pathway both in vitro and in vivo (10). Furthermore, TTRAP plays a key role in the maintenance of genomic stability. In 2009, TTRAP, also known as tyrosyl DNA phosphodiesterase-2 (TDP2), was shown to be the first 5'-tyrosyl DNA phosphodiesterase necessary for the repair of DNA double-strand breaks (11). Proteins derived from exogenous pathogens, such as Hantaan hantavirus (HTNV) nucleocapsid proteins, p53 and HIV-1 integrases, interact with TTRAP directly (12-14). TTRAP has also been identified as a novel promyelocytic leukemia nuclear body (PML NB) protein involved in the regulation of ribosome biogenesis (15, 16).

The maintenance of genome stability is central to cell survival. As the only 5'-tyrosyl DNA phosphodiesterase identified, TTRAP should play a role in cell growth and tumorigenesis. Although TTRAP has been reported to promote cell proliferation in NSCLC cells, its function may be different in other tumor cells. Here, we expressed TTRAP in two osteosarcoma cell lines, U2OS and Saos-2, through lentiviral infection. The profile of cell growth and apoptosis upon the ectopic expression of TTRAP was investigated. The relationship between mutations in the 5'-tyrosyl DNA phosphodiesterase motif of TTRAP and their effects on cell growth was also evaluated.
RESULTS

The overexpression of TTRAP inhibits the colony formation and cell growth of U2OS and Saos-2 cells

TTRAP has been reported to express ubiquitously. When detected with anti-TTRAP antibodies, the endogenous expression level of TTRAP varied widely among different cell lines (supplementary Fig. 1). U2OS, a human osteosarcoma cell line that has a relatively low level of endogenous TTRAP expression, was selected to evaluate the effects of TTRAP overexpression on cell growth and tumorigenesis in vitro. Saos-2, another human osteosarcoma cell line that shows deficient expression of p53, was also tested (17).

Exogenous TTRAP was introduced into U2OS and Saos-2 cells using a lentivirus expression system. The expression profile of EGFP and the TTRAP-EGFP fusion protein (derived from pWPXL and pWPXL-TTRAP, respectively) after viral infection was detected with FACS from day 1 to day 6. The proportion of EGFP-positive cells was 100% on day 2 (Supplementary Fig. 2). The maximum expression was maintained from day 3 (Supplementary Fig. 3). To abolish the potential cytotoxicity from EGFP expression, the open reading frame (ORF) of EGFP was removed from the parent lentivirus plasmid pWPXL to generate pWPXL-NE. Empty viruses (lenti-vector) and viruses expressing TTRAP without the EGFP tag (lenti-TTRAP) were produced with pWPXL-NE and pWPXL-NE-TTRAP, respectively. U2OS and Saos-2 cells were infected with lenti-vector and lenti-TTRAP. The improved expression of TTRAP in lenti-TTRAP-infected U2OS and Saos-2 cells was identified with Western blotting (Fig. 1A).

The inhibitory effect of TTRAP on the growth of osteosarcoma cells was first evaluated with a colony formation assay. The stable infection with lenti-TTRAP resulted in an obvious decrease in the number and size of colonies of U2OS and Saos-2 cells (Fig. 1B). Compared with the control, the colony count per well was reduced by 26.6% in U2OS cells and 34.4% in Saos-2 cells in the TTRAP overexpression groups (Fig. 1C). A variety of factors may result in the suppression of colony formation, such as the inhibition of cell growth or migration. Pei et al. and Zucchelli et al. reported that cells stably transfected with TTRAP showed no difference in cell growth in the absence of exogenous stress (5, 9). To determine whether TTRAP inhibited cell growth, we plated U2OS and Saos-2 cells three days after lentiviral infection and incubated the cells for 1-6 days. The cell viability was measured with MTT. Compared with the lenti-vector-infected control, the number of viable cells in the lenti-TTRAP-infected groups was reduced by 34.0% in U2OS cells (Fig. 1D) and 31.1% in Saos-2 cells (Fig. 1E) at the end of the incubation. These results indicated that TTRAP significantly inhibited cell growth in both cell lines.
TTRAP inhibits cell growth and induces apoptosis
Caihong Zhou, et al.

Effect of mutations in the 5′-tyrosyl DNA phosphodiesterase activity of TTRAP on cell growth
As a 5′-tyrosyl DNA phosphodiesterase, TTRAP restores the 5′-phosphate termini at DNA double-strand breaks in preparation for DNA ligation. To determine the functional domains associated with the inhibitory effect of TTRAP on cell growth, we constructed two plasmids expressing inactive TTRAP phosphodiesterase mutants, TTRAP<sup>E152A</sup> and TTRAP<sup>D262A</sup>, using the plasmid pcDNA-myc as a parent backbone. These plasmids and the control plasmid pcDNA-myc were introduced into U2OS cells through transient transfection. Anti-myc antibody was used to evaluate the expression of TTRAP and its mutants with Western blot assay. The levels of TTRAP<sup>E152A</sup> and TTRAP<sup>D262A</sup> expression were comparable, but both were lower than that of the wild type one (Fig. 2A). All of the transfected cells were incubated under neomycin selection, and the resulting colonies were counted. The ectopic TTRAP<sup>wt</sup> inhibited colony formation by 43.6% compared with vector-treated cells. The two inactive 5′-tyrosyl DNA phosphodiesterase mutants of TTRAP, TTRAP<sup>E152A</sup> and TTRAP<sup>D262A</sup>, showed variable effects on the growth of U2OS cells (Fig. 2B and 2C). Ectopic TTRAP<sup>E152A</sup> did not affect colony formation while TTRAP<sup>D262A</sup> decreased the clones' growth by 17%. Recombinant lentiviruses expressing TTRAP<sup>D262A</sup> were also prepared. In consistent with the results obtained in the transient transfection assay, TTRAP<sup>E152A</sup> lost the capacity of inhibiting colony formation in U2OS cells (Supplementary Fig. 4).

TTRAP induces cell cycle arrest and apoptosis in osteosarcoma cells
The growth inhibition of cells may be caused by a reduced cell proliferation rate, increased apoptosis or cell cycle arrest. We first investigated the effect of exogenous TTRAP on cell cycle distribution. Virus-infected cells were collected 24 h after plating, and the cell cycle profile was analyzed after PI staining. In U2OS cells, approximately 5.3% of the TTRAP-expressing cells were dead compared with 1.3% of the control cells, but no significant difference in the cell population in G2/M or G1 phase was detected between these two groups (Fig. 3A). In Saos-2 cells, approximately 6.8% of the TTRAP-expressing cells were dead compared with 4.0% of the control cells. Furthermore, ectopic TTRAP expression induced a significant increase in the cell population at G2/M phase and a decrease in the cell population at G1 phase compared with the control cell groups, which indicated a G2/M-phase cell cycle arrest (Fig. 3B).

To confirm whether TTRAP-induced cell death was caused by apoptosis, virus-infected cells were further evaluated through the detection of caspase-3/-7 activity after being serum-starved in 0.2% FBS for 2 days. The caspase-3/-7 activity in untreated cells was arbitrary set as the standard. The lenti-TTRAP infection increased the caspase-3/-7 activity by 2.3 fold in U2OS cells and
TTRAP inhibits cell growth and induces apoptosis
Caihong Zhou, et al.

1.2 fold in Saos-2 cells compared with the lenti-vector-treated cells (Fig. 4A). In addition, the cell survival of lenti-TTRAP-treated cells was significantly decreased (from 95.1% to 66.3% in U2OS cells and from 94.4% to 79.4% in Saos-2 cells), as shown in Fig. 4B, which indicates a significant increase in caspase activity and apoptosis in TTRAP-overexpressing cells. The mutant TTRAPE152A obviously lost the activity of TTRAPwt to induce apoptosis in both cell lines, which induced caspase-3/-7 activity comparable with the vector control.

TTRAP inhibits cyclin B1 expression in both U2OS and Saos-2 cells
The inhibitory effects of exogenous TTRAP expression on cell growth and colony formation might be caused by both cell cycle arrest and apoptosis. Cyclin B1 is a key regulator of G2/M transition of cell cycle. Exogenous TTRAPwt decreased the expression of cyclin B1 protein by 28.6% in U2OS cells (Fig. 4C and 4E) and 40.4% in Saos-2 cells (Fig. 4D and 4F), respectively. Exogenous TTRAPE152A lost the activity of TTRAPwt in inhibiting the expression of cyclin B1 in both U2OS and Saos-2 cells.

DISCUSSION
TTRAP is a multi-functional protein that controls a variety of cellular activities, including cell proliferation, apoptosis and DNA repair (2). Many studies have indicated that TTRAP may be responsible for aberrant cell growth and tumorigenesis. Although it has been reported that TTRAP facilitates the oncogenesis of non-small-cell lung carcinoma both in vitro and in vivo, its expression and function in osteosarcoma cells has not been explored. In the present study, we infected osteosarcoma cell lines with a recombinant lentivirus containing the ORF of TTRAP. The results demonstrated that exogenous TTRAP significantly inhibited the growth and colony formation capacity of osteosarcoma cells. Ectopic TTRAP induced cell apoptosis in both U2OS and Saos-2 cells. TTRAP also arrested cells in G2/M phase in Saos-2 cells. Various studies have shown the involvement of cell cycle regulation-mediated apoptosis as a mechanism of cell growth inhibition. Both in U2OS and Saos-2 cells, ectopic TTRAP decreased the expression of cyclin B1 protein, indicating that cell cycle arrest may account for the apoptosis in both cell lines. The discrepancy of TTRAP’s effects in different tumor cell lines can result from the complexity of the cell microenvironment and the TTRAP protein interaction network. The effect of TTRAP expression on the tumorigenesis of osteosarcoma in vivo was not clarified in this study. A breakthrough regarding TTRAP knockout animal models in the future may shed new light on TTRAP’s physiological functions, including its roles in the regulation of cell growth and tumorigenesis.

Many pathways can influence cell fate decisions upon exogenous stress. The data on TTRAP functions imply that it is involved in the response to different types of stress associated with chromosomal instability, such as DNA damage caused by irradiation, chemical reagents or viral infection. Being a member of the PML NB protein family, TTRAP is a relatively small protein compared with the classical members in the family, such as PML (18) and DAXX (19). Some structural properties may account for different activities among TTRAP’s multiple functions. The two
mutations in TTRAP’s 5’-tyrosyl-DNA phosphodiesterase activity, TTRAP\textsuperscript{E152A} and TTRAP\textsuperscript{D262A}, showed decreased inhibitory actions on cell growth. TTRAP\textsuperscript{E152A} also lost the activity of TTRAP\textsuperscript{wt} in inducing the increase of caspase-3/-7 activity and the decrease of cyclin B1 expression. This result demonstrated that the DNA repair activity of TTRAP was associated with its cell growth modulation capability in osteosarcoma cells.

MATERIALS AND METHODS

Plasmids

The ORF of TTRAP was amplified from a human fetal brain cDNA library (Clontech, Mountain View, CA). The mammalian expression vector pcDNA3.1-TTRAP was constructed as described previously (14). The cDNA sequences for the mutants TTRAP\textsuperscript{E152A} and TTRAP\textsuperscript{D262A} were generated with PCR using pcDNA3.1-TTRAP as a template and subcloned into the vector pcDNA3.1/myc-His(-) A (Life Technologies, Carlsbad, CA) between the EcoRI and BamHI sites. To express TTRAP with a lentiviral expression system, the ORF of TTRAP was inserted into pWPXL (Addgene, Cambridge, MA) between the BamHI and MluI sites to produce pWPXL-TTRAP, which expressed a TTRAP-EGFP fusion protein. The ORF of EGFP between the SmaI and PmeI sites was removed from pWPXL in order to produce pWPXL-NE-TTRAP, which expressed the TTRAP protein without the EGFP tag. The primers for constructing these plasmids are shown in Supplementary information Table S1. All of the constructs were verified with DNA sequence analysis.

Cell culture and transfection

HEK293T and U2OS cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) supplemented with 100 units/ml of penicillin and 100 μg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO₂. Saos-2 cells were grown in DMEM/F-12 supplemented with 15% FBS. The cells were transfected with Lipofectamine 2000 reagent (Life Technologies, Carlsbad, CA) for 24 h and then seeded at 4 × 10⁴ per well in a six-well plate. The number of stable colonies formed after selection in 800 μg/ml G418 (Sigma-Aldrich) for 12 days was counted.

Western blotting

Cells were washed with cold phosphate-buffered saline (PBS) and lysed in ice-cold buffer. The protein concentration was determined with the Bradford protein assay (Bio-Rad Laboratories, Hercules, CA). Protein extracts were resolved through 12% SDS-PAGE and transferred to a PVDF membrane (Millipore, Billerica, MA). The membranes were blocked in 5% fat-free milk and incubated with anti-human TTRAP polyclonal antibodies (Aviva Systems Biology, San Diego, CA), anti-myc (Santa Cruz Biotechnologies, Santa Cruz, CA), anti-cyclin B1 and anti-GAPDH (Cell Signaling Technology, Danvers, MA) antibodies at 4°C overnight. After washing with PBS, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies. The protein signals were visualized with an enhanced chemiluminescence immunoblotting detection kit (GE Healthcare, Piscataway, NJ). GAPDH was used as an equal loading control.

Cell cycle analysis

Cells grown in regular growth medium for 24 h were collected, fixed in 70% cold ethanol overnight and stained with PBS containing 50 μg/ml propidium iodide (PI) and 100 μg/ml RNase A (Tiangen Biotech, Beijing, China) for 30 min at 37°C. The DNA content of the labeled cells was measured using the Accuri C6 flow cytometry system (BD Biosciences).
**Detection of caspase-3/-7 activity**

The lenti-TTRAP- or lenti-vector-infected cells were seeded at a density of 500/well in triplicate wells in a 384-well plate. After an overnight incubation, the medium was replaced with DMEM supplemented with 0.2% FBS and incubated for another 48 h. Caspase activity was subsequently measured with a Caspase-Glo 3/7 Assay System (Promega, Fitchburg, WI) according to the manufacturer’s protocols. Briefly, an equal volume of caspase substrate was added to the cells, and the samples were incubated at room temperature for 1 h. The luminescence was measured using an EnVision 2103 Multilabel Reader (PerkinElmer, Waltham, MA). The luminescence of the untreated control cells was set as the standard.

**Statistical analysis**

The experiments were repeated at least three times, and the results were expressed as the mean ± SD. Student’s t-test was used to compare the values of the TTRAP overexpression samples with the vector control samples. A value of \( P < 0.05 \) was considered to be statistically significant.

**Acknowledgments**

We are very grateful to Dr. Hui X. for the valuable discussion. We also thank Wang B.Y. and Hu H. for their technical support. This work was supported by the National Basic Research Program of China (2010CB529903) and the Nature Science Fund (0971617).

**REFERENCES**

1. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell **100**, 57-70.
2. Li, C., Sun, S. Y., Khuri, F. R. and Li, R. (2011) Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond. Cell Cycle **10**, 3274-3283.
3. Pyper, S., Declercq, W., Ibrahimi, A., Michiels, C., Van Rietschoten, J. G., Dewulf, N., de Boer, M., Vandenabeele, P., Huybrechts, D. and Remacle, J. E. (2000) TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs) and that inhibits nuclear factor-kappa B activation. *J. Biol. Chem.* **275**, 18586-18593.
4. Lee, H. Y., Yoon, S. W., Kim, J. Y., Park, K. W., Hwang, C. I., Park, W. Y., Oh, B. H., Park, Y. B., Walsh, K., Seo, J. S. and Kim, H. S. (2008) FOXO3a turns the tumor necrosis factor receptor signaling towards apoptosis through reciprocal regulation of c-Jun N-terminal kinase and NF-kappaB. *Arterioscler. Thromb. Vasc. Biol.* **28**, 112-120.
5. Pei, H., Yordy, J. S., Leng, Q., Zhao, Q., Watson, D. K. and Li, R. (2003) EAPII interacts with ETS1 and modulates its transcriptional function. *Oncogene* **22**, 2699-2709.
6. Várady, G., Sarkadi, B. and Fátyol, K. (2011) TTRAP is a novel component of the non-canonical TRAF6-TAK1 TGF-β signal-transduction pathway. *PLoS One* **6**, e25548.
7. Zhang, Z. B., Hu, J., Bi, Y. Y., Zhao, Z. W., Tao, N., Yan, H., Zhu, Z. L., Liu, Y. M. and Li, L. (2007) Effect of TTRAP expression on apoptosis induced by hydroquinone in HL-60 cells in vitro. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* **25**, 654-656.
8. Esquerra, C. V., Nelles, L., Vermeire, L., Ibrahimi, A., Crawford, A. D., Derua, R., Janssens, E., Waelkens, E., Carmeliet, P., Collen, D., Collen, D. and Huybrechts, D. (2007) TTRAP is an essential modulator of Smad3-dependent Nodal signaling during zebrafish gastrulation and left-right axis determination. *Development* **134**, 4381-4393.
9. Zucchielli, S., Villoiti, S., Calligaris, R., Lavina, Z. S., Biagioli, M., Folt, R., De Maso, L., Pinto, M., Gorza, M., Speretta, E., Casseler, C., Tell, G., Del Sal, G. and Gustinich, S. (2009) Aggresome-forming TTRAP mediates pro-apoptotic properties of Parkinson’s disease-associated DJ-1 missense mutations. *Cell Death. Differ.* **16**, 428-438.
10. Li, C., Fan, S., Owxonikoko, T. K., Khuri, F. R., Sun, S. Y. and Li, R. (2011) Oncogenic role of EAPIII in lung cancer development and its activation of the MAPK-ERK pathway. *Oncogene* **30**, 3802-3812.
11. Cortes Ledesma, F., El Khamiys, S. F., Zuma, M. C., Osborn, K. and Caldecott, K. W. (2009) A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. *Nature* **461**, 674-678.
12. Lee, B. H., Yoshimatsu, K., Maeda, A., Ochiai K., Morimatsu, M., Araki, K., Ogino, M., Morikawa, S. and Arikawa, J. (2003) Association of the nucleosapid protein of the Seoul and Hantaan hantaviruses with small ubiquitin-like modifier-1-related molecules. *Virus Res.* **98**, 83-91.
13. Wang, B. Y., Xu, G. L., Zhou, C. H., Tian, L., Xue, J. L., Chen, J. Z. and Jia, W. (2010). PhiC31 integrase interacts with TTRAP and inhibits NF kappaB activation. *Mol. Biol. Rep.* **37**, 2809-2816.
14. Zhang, J. Q., Wang, J. J., Li, W. J., Huang, L., Tian, L., Xue, J. L., Chen, J. Z. and Jia, W. (2009) Cellular protein TTRAP interacts with HIV-1 integrase to facilitate viral integration. *Biochem. Biophys. Res. Commun.* **387**, 256-260.
15. Xu, G. L., Pan, Y. K., Wang, B. Y., Huang, L., Tian, L., Xue, J. L., Chen, J. Z. and Jia, W. (2008) TTRAP is a novel PML nuclear bodies-associated protein. *Biochem. Biophys. Res. Commun.* **375**, 395-398.
16. Villoiti, S., Biagioli, M., Folti, R., Ferro, D. M., Lavina, S. Z., Collavini, L., Sal, D. G., Zucchielli, S. and Gustinich, S. (2012) The PML nuclear bodies-associated protein TTRAP regulates ribosome biogenesis in nucleolar cavities upon proteasome inhibition. *Cell Death. Differ.* **19**, 488-500.
17. Masuda, H., Miller, C., Koefler, P. H., Battifora, H. and Cling, J. M. (1987) Rearrangement of the p53 gene in human osteogenic sarcomas. *Proc. Natl. Acad. Sci. U.S.A.* **84**, 7716-7719.
18. Jensen, K., Shiee, C. and Freemont, P. S. (2001) PML protein isoforms and the RBCC/TRIM motif. *Oncogene* **20**, 7225-7233.
19. Salomoni, P. and Khelifi, A. F. (2006) Daxx: death or survival protein? *Trends Cell Biol.* **16**, 97-104.